Recent advances in antiretroviral treatment and prevention in HIV-infected patients.
Recent advances in antiretroviral treatment and prevention in HIV-infected patients.
复制标题
DOI：
10.1097/01.coh.0000410238.80894.81
复制
发表时间：
2011-12-01
影响因子：
4.1
通讯作者：
Valente, Cristina
中科院分区：
文献类型：
--
作者：
Maltez, Fernando;Doroana, Manuela;Valente, Cristina
审查目的：讨论目前正在评估的新的抗逆转录病毒药物（ARV）和替代ARV治疗策略，并概述HIV疫苗开发的最新进展。持续需要改进ARV疗法（ART），并且几种新的ARV目前正在进行临床研究，包括非核苷逆转录酶抑制剂利匹韦林，整合酶抑制剂埃替格韦，趋化因子受体5共受体拮抗剂vicriviroc和成熟抑制剂bevirimat。优化抗逆转录病毒疗法的策略，如治疗中断、诱导维持和类保留方案，也正在进行评估，迄今为止取得了不同程度的成功。然而，疫苗接种仍然是最佳的解决方案，第二代预防性艾滋病毒疫苗在最近的III期试验中产生了令人鼓舞的结果。概要：在我们等待有效疫苗开发的同时，全球预防和治疗抗逆转录病毒药物有效，耐受性好，对艾滋病毒耐药性的发展具有高障碍，是抗击艾滋病毒/艾滋病的主要战略。
PURPOSE OF REVIEW: To discuss new antiretroviral agents (ARVs) and alternative ARV treatment strategies that are currently being evaluated, and to provide an overview of the most recent advances in HIV vaccine development.RECENT FINDINGS: There is a continuous need for improvements in ARV therapy (ART) and several new ARVs are currently undergoing clinical investigation, including the non-nucleoside reverse transcriptase inhibitor rilpivirine, the integrase inhibitor elvitegravir, the chemokine receptor 5 co-receptor antagonist vicriviroc and the maturation inhibitor bevirimat. Strategies to optimize ART, such as treatment interruption, induction-maintenance and class-sparing regimens, are also being evaluated and have had varying success to date. However, vaccination still remains the optimal solution, and one second-generation preventative HIV vaccine has produced encouraging results in a recent phase III trial.SUMMARY: Global prevention and treatment with ARVs that are effective, well tolerated and have high barriers to the development of HIV resistance are the main strategies to fight HIV/AIDS while we await the development of an effective vaccine.